DPP-IV Inhibitors

Global Market Trajectory & Analytics

MCP-6466

EXECUTIVE ENGAGEMENTS

POOL

4609
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

832
Interactions with Platform & by Email

PARTICIPANTS

138
Unique # Participated

VALIDATIONS

42
Responses Validated*

COMPANIES

16
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

18

PAGES

64

EDITION

16

PRICE

USD 5450

CODE

MCP-6466


COMPETITIVE METRICS

COMPANY

D S N T

% *

AstraZeneca PLC

Boehringer Ingelheim International GmbH

Daiichi Sankyo Co., Ltd.

Dong-A ST Co., Ltd.

Dr. Reddy`s Laboratories Ltd.

Eli Lilly and Company

Glenmark Pharmaceuticals Ltd.

Kowa Co., Ltd.

Kyowa Kirin Co., Ltd.

Lupin Ltd.

*Login to Participate & View Data Stacks
View 16 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for DPP-IV Inhibitors estimated at US$8.9 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 2.3% over the period 2020-2027.
The DPP-IV Inhibitors market in the U.S. is estimated at US$2.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 2.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 1.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

SELECT PLAYERS

AstraZeneca Plc.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck & Co. Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis AG; Takeda Pharmaceutical Company Limited

SEGMENTS

» Segment (DPP-IV Inhibitors)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks
Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
Recent Market Activity
TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
Management of T2DM with DPP-4 Combination Therapy
FDA Approves Merck’s First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Eli Lilly and Company (USA)
Merck & Co, Inc. (USA)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
CANADA
Canada Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
JAPAN
Japan Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
CHINA
China Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
EUROPE
Europe Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
FRANCE
France Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
GERMANY
Germany Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
ITALY
Italy Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Total Companies Profiled: 16

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com